Core Viewpoint - The company, Aopumai (688293.SH), announced that its wholly-owned subsidiary, Shanghai Silun Biotechnology Co., Ltd. (referred to as "Silun Biotechnology"), successfully passed the Qualified Person (QP) audit by the European Union, receiving a compliance audit report [1] Group 1 - The successful completion of the QP audit indicates that Silun Biotechnology's quality management system meets the EU GMP regulatory requirements [1] - This achievement ensures high-quality research and production services in the field of macromolecular biopharmaceuticals [1] - The compliance lays a solid foundation for the company to further expand into international markets, including the EU [1]

Core Viewpoint - Aopu Mai (688293.SH) has successfully passed the Qualified Person (QP) audit conducted by its wholly-owned subsidiary, Shanghai Silun Biotechnology Co., Ltd, marking a significant achievement in meeting EU GMP regulatory requirements [1] Group 1: Company Achievements - The successful QP audit indicates that Silun Biotechnology's quality management system meets the standards set by EU GMP regulations [1] - This achievement ensures high-quality research and production services in the field of macromolecular biopharmaceuticals [1] Group 2: Market Implications - The compliance with EU standards lays a solid foundation for the company to expand into international markets, including the EU [1]